ライフサイエンスコーパス: no serious adverse events

コーパス検索結果 (right1)

通し番号をクリックするとPubMedの該当ページを表示します

1 Study drugs were well tolerated with no serious adverse events.

2 (risk difference, 5.0%; 95% CI, 1.6%-8.4%; P = .005), with no serious adverse events.

3 There were no serious adverse events.

4 ACP-501 was well tolerated, and there were no serious adverse events.

5 Treatment was well tolerated, with no serious adverse events.

6 Although a potent blocker of hERG, it produced no serious adverse events.

7 tolerated with no signals for a safety concern; there were no serious adverse events (AEs) or discontinuations due to AE

8 There were no serious adverse events and all patients reported that the

9 There were no serious adverse events and no withdrawals from the study.

10 No serious adverse events associated with the treatment were

11 No serious adverse events, discontinuations, or deaths were a

12 ved a total of 249 IV infusions and 208 SC injections, with no serious adverse events, dose-limiting toxicities, nor evid

13 There were no serious adverse events (grade 2-4) and asexual parasites w

14 omas and one major cardiovascular adverse event; there were no serious adverse events in the 180-mg risankizumab group.

15 There were no serious adverse events, including allergic reaction, repor

16 No serious adverse events led to withdrawal from the study.

17 No serious adverse events occurred during or after vector inf

18 No serious adverse events occurred in either group.

19 No serious adverse events occurred.

20 No serious adverse events occurred.

21 No serious adverse events occurred.

22 All 23 participants tolerated the regimen well; there were no serious adverse events or adverse event-related discontinu

23 There were no serious adverse events or discontinuations due to adverse

24 We recorded no serious adverse events or signs of liver or muscle toxic e

25 No serious adverse events related to botulinum toxin use were

26 The majority of adverse events were mild in severity; no serious adverse events related to study drug and no releva

27 No serious adverse events related to tenofovir use were repor

28 creases in specific antibody to rh-FGF-2 were detected, and no serious adverse events related to the products were report

29 There were no serious adverse events related to the study drug.

30 olerated; six mild local reactions occurred, and there were no serious adverse events related to the study medication.

31 GSK2330672 treatment for 14 days was safe with no serious adverse events reported.

32 No serious adverse events requiring hospitalisation were repo

33 No serious adverse events (SAEs) were attributable to study d

34 No serious adverse events were associated with receipt of imm

35 No serious adverse events were attributed to GEN-003.

36 (93.9%) patients successfully swallowed the Cytosponge, and no serious adverse events were attributed to the device.

37 In this phase 1 trial, no serious adverse events were observed with inclisiran.

38 No serious adverse events were observed.

39 No one lost vision, and no serious adverse events were observed.

40 cases [2.8%]) than in the control group (ten cases [0.8%]); no serious adverse events were observed.

41 No serious adverse events were recorded.

42 No adverse events led to discontinuation of study drug, and no serious adverse events were related to study drug.

43 No serious adverse events were related to vaccination.

44 No serious adverse events were reported and adverse events di

45 No serious adverse events were reported.

46 No serious adverse events were reported.

47 mastine fumarate treatment was associated with fatigue, but no serious adverse events were reported.

48 No serious adverse events were reported; there were no signif

49 No serious adverse events were study-related; medical hospita

50 Ninety biopsy procedures were performed with no serious adverse events, with a mean of 3.7 targets sampled

WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。